Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histamine H2, H3, and H4 receptors are distinct G protein-coupled receptors (GPCRs) that mediate the physiological and pathological effects of histamine across various organ systems [1.1.1, 1.3.5]. The H2 receptor is primarily expressed in the gastric parietal cells, where it stimulates gastric acid secretion via Gs-protein signaling, and is a major target for treating peptic ulcers and gastroesophageal reflux disease [1.4.1, 1.4.3]. The H3 receptor serves as a presynaptic autoreceptor and heteroreceptor in the central nervous system, modulating the release of histamine and other neurotransmitters like dopamine and acetylcholine to regulate sleep, cognition, and appetite [1.1.3, 1.1.5]. The H4 receptor is predominantly found on immune cells, such as mast cells and eosinophils, where it mediates chemotaxis and inflammatory signaling through Gi/o-protein pathways [1.3.1, 1.3.4]. Therapeutic interventions include H2 antagonists for gastrointestinal disorders, H3 inverse agonists for narcolepsy and cognitive impairment, and H4 antagonists currently being explored for allergic and autoimmune diseases [1.2.1, 1.3.3]. While H2 and H3 receptors have well-established clinical applications, the H4 receptor remains a focus of intense research for its potential in treating chronic inflammatory conditions [1.2.1, 1.3.5]. The diversity in their signaling pathways and tissue distribution allows for highly specific pharmacological targeting, although cross-reactivity and systemic side effects remain therapeutic challenges [1.2.2, 1.4.5].
Drugs targeting these receptors primarily act as antagonists or inverse agonists to modulate histamine signaling. H2 receptor antagonists competitively block H2 receptors on gastric parietal cells to suppress acid secretion [1.4.3, 1.4.5]. H3 receptor antagonists/inverse agonists block presynaptic H3 autoreceptors, thereby increasing the synthesis and release of histamine and other neurotransmitters in the brain to promote wakefulness and cognitive function [1.1.2, 1.1.5]. H4 receptor antagonists inhibit the recruitment and activation of immune cells, such as eosinophils and mast cells, to reduce inflammation and pruritus in allergic conditions [1.3.2, 1.3.4].
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histamine H2, H3, and H4 receptors (H2R, H3R, and H4R).